ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The Effects of Natesto For Treatment Of Hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 195388" data-attributes="member: 13851"><p>[URL unfurl="true"]https://clinicaltrials.gov/ct2/show/NCT04717362[/URL]</p><p></p><p></p><p>Sponsor:</p><p><strong>Baylor College of Medicine</strong></p><p></p><p>Information provided by (Responsible Party):</p><p><strong>Larry I. Lipshultz, Baylor College of Medicine</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Detailed Description:</strong></p><p></p><p>Testosterone replacement therapy (TTh) is becoming increasingly common among men of reproductive age in the United States. An estimated 3 million men are on TTh;<em><strong> however exogenous testosterone use can disrupt the hypothalamus-pituitary-gonadal (HPG) axis, leading to reduced spermatogenesis and possible infertility.</strong></em> In normal physiology, the hypothalamus releases Gonadotropin-releasing hormone (GnRH), which stimulates the anterior pituitary to release Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). FSH then stimulates the Sertoli cells in the testis to support spermatogonial differentiation and maturation. LH stimulates the Leydig cells in the testes to produce endogenous testosterone. Regulation of this HPG axis occurs via negative feedback where testosterone directly inhibits the release of GnRH and LH from the hypothalamus and pituitary, respectively. <em><strong>The use of exogenous testosterone thus leads to reduced Sertoli function causing diminished spermatogenesis.</strong></em></p><p></p><p><strong><em>The spontaneous recovery of spermatogenesis after cessation of TTh is possible but may take months to years and cause the patient to experience a new onset of severe hypothalamic hypogonadal symptoms.</em> </strong>Human chorionic gonadotropin (HCG) is a naturally occurring protein that mimics LH and may be used as a therapy to support the return of spermatogenesis quickly with minimal side effects and resolve hypogonadal symptoms. <strong><em>Studies have shown that testosterone-induced infertile patients can recover sperm in the ejaculate in 4.6 months when treated with HCG supplemented with clomiphene citrate, tamoxifen, anastrozole, or recombinant FSH.</em></strong> With the cessation of TTh, despite the use of LH stimulatory protocols, these patients still experience hypogonadal symptoms. Recent preliminary results show the potential to offset hypogonadism symptoms that accompany exogenous testosterone cessation through the administration of 4.5% intranasal testosterone gel. Natesto is a nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator that administers 125uL (5.5mg of testosterone). <strong><em>Previous studies have shown that a single nasal dose has a rapid absorption with a Tmax at 60 mins and a half-life that ranged between 10-100 minutes. Three to four daily doses achieve eugonadal levels of circulating testosterone comparable to normal pulsatile-regulated release of testosterone. It has also been shown that men on Natesto maintain FSH and LH levels as well as total motile sperm count within the normal range. </em></strong>I<u>n</u> this prospective study, the investigators seek to confirm the role of Natesto to combat hypogonadal symptoms in men trying to recover spermatogenesis following the withdrawal of conventional TTh.</p><p></p><p></p><p></p><p>[ATTACH=full]12746[/ATTACH]</p><p>[ATTACH=full]12747[/ATTACH]</p><p>[ATTACH=full]12748[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 195388, member: 13851"] [URL unfurl="true"]https://clinicaltrials.gov/ct2/show/NCT04717362[/URL] Sponsor: [B]Baylor College of Medicine[/B] Information provided by (Responsible Party): [B]Larry I. Lipshultz, Baylor College of Medicine Detailed Description:[/B] Testosterone replacement therapy (TTh) is becoming increasingly common among men of reproductive age in the United States. An estimated 3 million men are on TTh;[I][B] however exogenous testosterone use can disrupt the hypothalamus-pituitary-gonadal (HPG) axis, leading to reduced spermatogenesis and possible infertility.[/B][/I] In normal physiology, the hypothalamus releases Gonadotropin-releasing hormone (GnRH), which stimulates the anterior pituitary to release Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). FSH then stimulates the Sertoli cells in the testis to support spermatogonial differentiation and maturation. LH stimulates the Leydig cells in the testes to produce endogenous testosterone. Regulation of this HPG axis occurs via negative feedback where testosterone directly inhibits the release of GnRH and LH from the hypothalamus and pituitary, respectively. [I][B]The use of exogenous testosterone thus leads to reduced Sertoli function causing diminished spermatogenesis.[/B][/I] [B][I]The spontaneous recovery of spermatogenesis after cessation of TTh is possible but may take months to years and cause the patient to experience a new onset of severe hypothalamic hypogonadal symptoms.[/I] [/B]Human chorionic gonadotropin (HCG) is a naturally occurring protein that mimics LH and may be used as a therapy to support the return of spermatogenesis quickly with minimal side effects and resolve hypogonadal symptoms. [B][I]Studies have shown that testosterone-induced infertile patients can recover sperm in the ejaculate in 4.6 months when treated with HCG supplemented with clomiphene citrate, tamoxifen, anastrozole, or recombinant FSH.[/I][/B] With the cessation of TTh, despite the use of LH stimulatory protocols, these patients still experience hypogonadal symptoms. Recent preliminary results show the potential to offset hypogonadism symptoms that accompany exogenous testosterone cessation through the administration of 4.5% intranasal testosterone gel. Natesto is a nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator that administers 125uL (5.5mg of testosterone).[U] [/U][B][I]Previous studies have shown that a single nasal dose has a rapid absorption with a Tmax at 60 mins and a half-life that ranged between 10-100 minutes. Three to four daily doses achieve eugonadal levels of circulating testosterone comparable to normal pulsatile-regulated release of testosterone. It has also been shown that men on Natesto maintain FSH and LH levels as well as total motile sperm count within the normal range. [/I][/B]I[U]n[/U] this prospective study, the investigators seek to confirm the role of Natesto to combat hypogonadal symptoms in men trying to recover spermatogenesis following the withdrawal of conventional TTh. [ATTACH type="full" alt="Screenshot (3416).png"]12746[/ATTACH] [ATTACH type="full" alt="Screenshot (3417).png"]12747[/ATTACH] [ATTACH type="full" alt="Screenshot (3418).png"]12748[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
The Effects of Natesto For Treatment Of Hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top